Publications
- Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic2023 | First Faculty of Medicine, Third Faculty of Medicine
- Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Efficacy of biological treatment of moderate to severe psoriasis - analysis from the BIOREP Registry2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- Porokeratoses2016 | First Faculty of Medicine
- Drug fever as an adverse effect of acitretin in complicated psoriasis patient2015 | Second Faculty of Medicine
- Juvenile generalized pustular psoriasis treated with etanercept2014 | Second Faculty of Medicine
- Immunosuppressants 2nd part2012 | Second Faculty of Medicine
- Immunosuppressants. 1st part2011 | Second Faculty of Medicine
Loading network view...